Stock Trading History of Lapalme Pierre

The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Lapalme Pierre since year 2005. The trader's CIK number is 1114913. At the time of this reporting, Lapalme Pierre is the Director of First Horizon Pharmaceutical Corp . (stock ticker symbol FHRX). See this page for all insider trading activities at First Horizon Pharmaceutical Corp .
Note that in the past LAPALME PIERRE also reported insider trading activities as an insider of the following companies:

Insider Activities at First Horizon Pharmaceutical Corp (FHRX)
Insider Activities at Biomarin Pharmaceutical Inc (BMRN)

Stock purchases, sales, and option exercises reported by insider *Lapalme Pierre* since 2005.
Trade Date	Symbol	Company Name (Issuer)	Trade Type	Shares	Price ($)	Value ($)
2008-05-23	SCRX	First Horizon Pharmaceutical Corp	Option Exercise	3,750	.00	0
2008-05-23	SCRX	First Horizon Pharmaceutical Corp	Sale	3,750	21.08	79,050
2008-03-17	SCRX	First Horizon Pharmaceutical Corp	Purchase	2,000	18.42	36,840
2008-03-17	SCRX	First Horizon Pharmaceutical Corp	Purchase	2,000	18.42	36,840
2008-02-29	BMRN	Biomarin Pharmaceutical Inc	Sale	5,975	38.25	228,518
2008-02-29	BMRN	Biomarin Pharmaceutical Inc	Option Exercise	15,000	5.92	88,800
2008-02-29	BMRN	Biomarin Pharmaceutical Inc	Sale	9,025	37.79	341,026
2007-09-04	SCRX	First Horizon Pharmaceutical Corp	Sale	14,250	25.38	361,665
2004-04-25	SCRX	First Horizon Pharmaceutical Corp	Option Exercise	14,250	5.33	75,995
2006-12-12	BMRN	Biomarin Pharmaceutical Inc	Purchase	2,100	17.88	37,555
2006-08-07	BMRN	Biomarin Pharmaceutical Inc	Purchase	1,000	15.35	15,350
2006-02-27	BMRN	Biomarin Pharmaceutical Inc	Purchase	3,500	12.98	45,441

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Lapalme Pierre (Director of First Horizon Pharmaceutical Corp at the time of this reporting) see the Securities and Exchange Commission (SEC) website.